DOP099 Five-year safety results from the ENCORE registry: Malignancies in patients with Crohn's disease treated with infliximab, standard therapy, or switched from standard therapy to infliximab

✍ Scribed by D'Haens, G.; Reinisch, W.; Colombel, J.-F.; Panes, J.; Ghosh, S.; Prantera, C.; Lindgren, S.; Hommes, D.W.; Huang, Z.; Huyck, S.; Chitkara, D.K.

• Book ID: 122275788
• Publisher: Oxford University Press
• Year: 2014
• Tongue: English
• Weight: 47 KB
• Volume: 8
• Category: Article
• ISSN: 1873-9946
• DOI: 10.1016/S1873-9946(14)60124-0